Anthos Takes On Pharma Giants In Factor XI Anticoagulation Space
Start-Up Was First To Start A Phase III Trial
CEO John Glasspool spoke with Scrip about why Anthos believes it has a good shot against big competitors in a market that is expected to generate blockbuster sales across multiple products.
You may also be interested in...
CMO Eliav Barr On Merck & Co.'s Post-Keytruda Game Plan
Merck & Co. chief medical officer Eliav Barr talks with Scrip about the generational leadership change under way at the company, Merck's next oncology plays and its bold plan to rebuild a cardiovascular franchise.
BMS/Janssen Will Begin Phase III For Factor XIa Inhibitor Milvexian By Year-End
Bristol and Janssen reported Phase II data at the ESC Congress in secondary stroke prevention, an indication not covered by Factor Xa inhibitors. BMS unveiled a three-indication Phase III program.
D-Day Approaches For Bayer’s Asundexian Phase III Plans
With Nubeqa establishing itself as a strong option for prostate cancer, Bayer is shifting its short-term focus from oncology onto cardiovascular and plotting a late-stage plan for asundexian, its follow-up to Xarelto.